@steven's GLP-1 story claims, fact-checked

What did @steven actually say?

@steven walked through a real New York Times case study about a woman named Stacey Canterbury who regained 20 pounds in one month after stopping a GLP-1 medication due to insurance issues. He described her returning hunger as "ferocious, animalistic" and argued the appetite comes back "with a vengeance" because the body feels like it has been starving. He also flagged muscle and bone loss, a signal for kidney cancer, and a black box thyroid cancer warning. He ended with a nuanced take: yes, these drugs help people with obesity, but he is skeptical about people using them to lose "10 pounds." The framing was mostly balanced, with a clear acknowledgment that data on long-term outcomes is largely positive when weight is actually lost.

Does the science back this up?

On weight regain after stopping, yes, the data is pretty clear and @steven gets the broad strokes right. The STEP 1 trial extension (Wilding et al., 2022, NEJM) showed participants regained about two-thirds of lost weight within one year of stopping semaglutide. The "rebound hunger" framing is plausible but slightly dramatized.

On muscle loss, the 40% figure he cites is real but context-dependent. A 2023 analysis by Wilding and colleagues noted that in trials without structured resistance training, lean mass loss accounted for roughly 25-40% of total weight lost. That range is accurate, but it is not inevitable. Studies including resistance training, like data from the SURMOUNT-1 extension, show substantially better lean mass preservation.

The thyroid cancer warning is accurately described as coming from rodent data only. The kidney cancer signal is a genuine area of ongoing pharmacovigilance. A 2024 JAMA Internal Medicine analysis flagged a potential signal in observational data, though causality has not been established.

What did they get wrong (or right)?

@steven gets credit for accurately describing the thyroid cancer black box as animal-derived and not confirmed in humans. That is a nuance many creators skip entirely. He also correctly notes that weight loss itself drives most of the disease-risk reduction, which makes it hard to isolate the drug's independent effect.

Where he oversimplifies: the "ferocious" hunger rebound story is compelling, but individual anecdotes from a newspaper article are not the same as mechanistic evidence. The physiological explanation he offers, that the body thinks it has been "starving," is a loose interpretation. What researchers actually observe is a rebound in ghrelin and a reduction in GLP-1 receptor sensitivity after discontinuation, which is a more specific mechanism than general starvation response.

His claim that tapering the dose helps slow weight regain is plausible but not well-supported by controlled trials. There is limited peer-reviewed data on structured tapering protocols specifically for GLP-1 agonists, so presenting it as established guidance goes a bit further than the evidence currently supports.

What should you actually know?

GLP-1 medications are not a permanent fix if you stop taking them. The STEP 1 extension data (Wilding et al., 2022) is the clearest evidence: weight, blood pressure, and cardiometabolic markers all largely returned toward baseline within a year of stopping. That is not a scandal, it is pharmacology. A drug that works while you take it is still a drug that works.

Muscle loss during GLP-1 therapy is a legitimate clinical concern, not a scare story. But it is addressable. Studies consistently show that adequate protein intake (at least 1.2 grams per kilogram of body weight) combined with resistance training significantly reduces lean mass loss. The 40% figure applies to people doing neither of those things.

The kidney cancer signal and thyroid cancer warning deserve honest communication with a prescribing clinician, not panic from a TikTok video. Neither is a confirmed causal link in humans at this point. Anyone with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not be on these medications. That is already a contraindication in the label.

Who is this video actually for?

@steven's closing point, that these drugs are being overused by people trying to lose 10 pounds, reflects a real clinical tension. GLP-1 agonists are FDA-approved for BMI thresholds and specific comorbidities. Using them outside those indications is off-label and carries the same risks without the same established risk-benefit ratio. His skepticism here is reasonable, though "10 pounds" is a rhetorical shorthand rather than a clinical threshold. The actual question is whether someone meets criteria and has had a real conversation with a provider about risks, benefits, and what happens if they stop.